OGEN - Oragenics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.9300
+0.0025 (+0.27%)
As of 3:15PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.9275
Open0.9900
Bid0.94 x 900
Ask0.94 x 1300
Day's Range0.9250 - 0.9799
52 Week Range0.3800 - 4.2000
Volume740,805
Avg. Volume8,471,871
Market Cap27.373M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • ACCESSWIRE11 days ago

    Oragenics Fast Track Drug AG013 Going into Phase II Clinicals, Pipeline Review

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Oragenics, Inc. (OGEN) a company focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. OGEN's product AG013, which has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe, is an Intrexon Actobiotics therapeutic candidate formulated to deliver the therapeutic molecule, human Trefoil Factor 1, to the mucosal tissues in the oral cavity in a convenient oral rinsing solution.

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / There was no news to explain the new high that Intec Pharma hit on Friday but Oragenics surged over 30% after announcing the publication of a research paper last week. Oragenics, Inc. shares closed up 33.66% on Friday with around 24.7 million shares traded. It was early last week that the company announced the publication of a research paper called "Blueprints for the rational design of therapeutic mutacin 1140 variants." The study focused on structure-activity relationships of the lantibiotic Mutacin 1140 (MU1140) that expand the “drugability” of the MU1140 pipeline.

  • Business Wire17 days ago

    Oragenics, Inc. Announces Publication Detailing the Development of Blueprints for Designing a New Class of Anti-Infectives

    Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced the publication of a research paper titled “Blueprints for the rational design of therapeutic mutacin 1140 variants,” in Chemical Biology & Drug Design (CBDD). The company has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries, which allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

  • ACCESSWIRE18 days ago

    Oragenics, Inc. to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 26, 2018 / Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM) today announced that it will be presenting at the 11th annual LD Micro Main Event on Thursday, December 6th at 9:30 AM PST, 12:30 PM EST. Dr. Alan Joslyn, Chief Executive Officer of Oragenics, Inc. will be presenting and meeting with investors. The LD Micro Main Event will take place December 4th, 5th, and 6th, in Los Angeles at the Luxe Sunset Bel Air Hotel, will feature 250 companies, and will be attended by over 1,200 individuals.

  • GlobeNewswire18 days ago

    Recent Analysis Shows Liberty Global, New Oriental Education & Technology Group, Platinum Group Metals, Asure Software, Oragenics, and MGE Energy Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Zacks Small Cap Research25 days ago

    OGEN: Phase 2 Trial of AG013 Adds Clinical Sites in Europe…

    Oragenics, Inc. (OGEN) is currently conducting a Phase 2, double blind, placebo controlled clinical trial of AG013 (NCT03234465). Approximately 160-180 subjects with head and neck cancer receiving chemotherapy will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s chemotherapy plan).

  • Business Wire29 days ago

    Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute and patients residing in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA), into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM. “We are pleased with the receipt of regulatory Health Authority approvals in Germany and the United Kingdom.

  • Business Wirelast month

    Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results for the quarter ended September 30, 2018. Total operating expenses, which include research and development and general and administrative expenses were $2.8 million for the third quarter of 2018, compared to $1.9 million for the same period during 2017.

  • Associated Presslast month

    Oragenics: 3Q Earnings Snapshot

    On a per-share basis, the Tampa, Florida-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 97 cents. A year ago, they were trading at $3.68. ...

  • ACCESSWIRElast month

    Positive Global Healthcare Outlook Could Push 3 Stocks Higher

    CORAL GABLES, FL / ACCESSWIRE / October 30,2018 / new reports from Deloitte, Exponential technologies are driving less expensive, more efficient, and more accessible care delivery on a global scale. Furthermore, Deloitte says that digital technology, robotics, and other automated tools have "enormous potential" to resolve current and future healthcare workforce pain points. Health care providers should embrace strategies where talent can collaborate with technology to improve efficiency instead of competing against each other.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Fresenius Medical Care and Oragenics

    NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Oragenics was gaining on Wednesday after announcing it has received clearance to enroll patients into a Phase 2 clinical trial. Shares of Fresenius Medical Care were deep in the red as traders digested the company’s slashed guidance for the third quarter. Fresenius Medical Care AG & Co. KGaA shares closed down nearly 17% on about 1.1 million shares traded yesterday.

  • Business Wire2 months ago

    Oragenics, Inc. Receives Clearance to Enroll Patients in Belgium into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced it has received clearance to enroll patients residing in Belgium from the Belgian Health Authority, The Federal Agency for Medicines and Health Products (FAMHP), into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. The Dow ...

  • ACCESSWIRE2 months ago

    This Week’s Biotech and Cannabis Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Stocks in the biotech and cannabis industries provide investors the largest gains. That’s why we always have our ear to the ground for the best opportunities ...

  • Simply Wall St.2 months ago

    Should You Worry About The Oragenics Inc’s (NYSEMKT:OGEN) Shareholder Register?

    If you want to know who really controls Oragenics Inc (NYSEMKT:OGEN), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • ACCESSWIRE2 months ago

    These Stocks Are on The Brink of Breakouts

    While it may be a little late on VSTM, there is another company working on a solution to the same cancers that has made impressive progress recently and could be the next major success story in the sector, Propanc Biopharma, Inc. (PPCB). PPCB is an intriguing biotech firm, that erupted for over 7000% last month going from a low of $0.0039 to a high of over $0.28, the stock is still holding a substantial gain as of the close on Wednesday. PPCB may start receiving increased attention from the street at any moment.

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Oct. 4, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • ACCESSWIRE2 months ago

    Biotech Market is Rolling and These Companies Need to Be on Your Radar

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / If you're an investor looking to make huge gains fast, Biotech and Cannabis stocks provide the best opportunity. Each market has a huge following of investors ...

  • Business Wire3 months ago

    Oragenics, Inc. to Present at Upcoming Conferences in October

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at The MicroCap Conference on October 1, 2018, at 1:00 PM ET as part of Track 1 at The Essex House in New York City. Interested investors may request a one-on-one meeting at The MicroCap Conference by registering for the meeting at www.microcapconf.com, or at the Ladenburg Thalmann 2018 Healthcare Conference by emailing HealthcareConference@ladenburg.com. We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Oragenics and Pfizer

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / It was a good day for biotech stocks Pfizer and Oragenics this past Friday. While Oragenics did not have any news, the company is expected to present data ...

  • Can Oragenics Inc (NYSEMKT:OGEN) Improve Your Portfolio Returns?
    Simply Wall St.3 months ago

    Can Oragenics Inc (NYSEMKT:OGEN) Improve Your Portfolio Returns?

    If you own shares in Oragenics Inc (NYSEMKT:OGEN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure ofRead More...

  • Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)?
    Simply Wall St.3 months ago

    Have Investors Priced In Healthcare Growth For Oragenics Inc (NYSEMKT:OGEN)?

    Oragenics Inc (NYSEMKT:OGEN), a US$5.0m small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronicRead More...

  • Business Wire3 months ago

    Oragenics, Inc. to Present Data from Its Lantibiotics Program at the Boulder Peptide Symposium Monday, September 24, 2018

    Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced that Dr. Martin Handfield, the company’s senior vice president of discovery research will present data on its lantibiotics program for the treatment of serious and prevalent infectious diseases at the Boulder Peptide Symposium on Monday, September 24, 2018 at 12:55 PM MT at the St. Julien Hotel and Spa in Boulder, CO.

  • Zacks Small Cap Research4 months ago

    OGEN: Positive DSMB Review for Phase 2 Trial of AG013…

    Oragenics, Inc. (OGEN) is currently conducting a Phase 2, double blind, placebo controlled clinical trial of AG013 (NCT03234465). AG013 is an oral mouth rinse composed of a recombinant L. lactis strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. Approximately 160-180 subjects with head and neck cancer receiving chemotherapy will receive either AG013 (2.0 x 1011 CFU) or placebo administered three times a day over 7-9 weeks (depending on the subject’s chemotherapy plan).

  • Business Wire4 months ago

    Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

    Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential treatment of OM following a positive review by an independent Data Safety Monitoring Board (DSMB). In May 2018, Oragenics reported positive interim safety analysis results based on the first 19 patients, which were evaluated on the basis of treatment-emergent adverse events, vital signs, weight, physical examination, clinical laboratory assessment and the potential presence of AG013 in blood.